Annotation Detail
Information
- Associated Genes
- VHL
- Associated Variants
-
VHL LOSS
(
ENST00000256474.3 )
VHL LOSS ( ENST00000256474.3 ) - Associated Disease
- renal cell carcinoma
- Source Database
- CIViC Evidence
- Description
- A meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC. Six studies (total of 633 patients) were included. 61,8% had a VHL mutation. The meta-analysis showed no association between the VHL gene alteration and overall response rate or progression free survival. There was also no correlation to overall survival. VEGFR inhibition included: Sunitinib, Sorafenib, Axitinib, Pazopanib, Bevacizumab.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4830
- Gene URL
- https://civic.genome.wustl.edu/links/genes/58
- Variant URL
- https://civic.genome.wustl.edu/links/variants/436
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Renal Cell Carcinoma
- Evidence Direction
- Does Not Support
- Drug
- Anti-VEGF Monoclonal Antibody
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 28103578
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Anti-VEGF Monoclonal Antibody | Sensitivity | false |